Clinical Trial News

Wegovy users had 33% lower Covid-19 death risk in a trial, with immediate protection before weight loss. All-cause death rates also dropped, suggesting obesity treatment improves life expectancy.

Eli Lilly announced retatrutide's trial results at ESC 2024, showing it reduced non-HDL-C, apoB, triglycerides, and improved lipid profiles in obese patients, potentially revolutionizing obesity treatment.

A rare, fatal disease called SPG50 affects fewer than 100 people globally, including 3-year-old Naomi Lockard. An experimental genetic therapy shows promise but is too expensive for most families. Naomi's mother, Rebekah Lockard, is raising funds for the therapy, which has shown success in stopping the disease's progression in clinical trials, but the trial has run out of funding.

The ABYSS trial suggests continuing beta-blockers may not be necessary for post-MI patients with preserved ejection fraction, but further research is needed. Results showed no safety preservation or quality of life benefits with beta-blocker interruption, with similar rates of death, MI, and stroke between groups, but higher rates of cardiovascular hospitalizations in the interruption group.

NIH grants $15.5m to establish NEXT STEPs network to include nursing home residents in clinical trials, led by Dr Kathleen Unroe, aiming to address their underrepresentation and enhance care quality.

A prospective, randomized, blind, crossover clinical trial involving healthy subjects evaluated the effects of dark and milk chocolate on retinal perfusion and vascular response using OCT-A and DVA. Subjects underwent ophthalmologic evaluations before and after chocolate consumption, with primary outcomes focusing on changes in retinal perfusion and vascular response to flicker stimulation post-dark chocolate intake. The study adhered to ethical standards and was approved by the San Raffaele Ethics Committee.

New studies reveal Ozempic and Wegovy, both versions of semaglutide, offer health benefits beyond weight loss, including reducing heart failure risks, COVID-19 deaths, and all-cause mortality. Presented at the European Society of Cardiology meeting and published in the Journal of the American College of Cardiology, the findings suggest these drugs could revolutionize cardiovascular care.

Get the ABC listen app to take your favourite podcasts and radio with you.

Nurix Therapeutics' NX-1607, an oral CBL-B inhibitor, is in clinical trials to enhance T cell activation, addressing limitations of immune checkpoint inhibitors. Initial results presented at ACS Spring 2024.

New pooled analysis in The Lancet shows semaglutide reduces risk of combined CV death or worsening heart failure by 31%, with a 41% lower risk of worsening HF. Semaglutide not approved for heart failure outcomes in the US. Analysis included 3,743 HFpEF patients from four trials.